NASDAQ · HALO
Halozyme Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HALO: Nov 05, 2026
Halozyme Therapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $2.16. The reported EPS for the same quarter last year was $1.63.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.16 | $2.21 | $2.06 | 3 |
| Dec 2026 | $2.51 | $2.61 | $2.40 | 3 |
| Mar 2027 | $1.98 | $2.17 | $1.78 | 2 |
| Jun 2027 | $2.35 | $2.66 | $2.04 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest- Zacks · Oct 29, 9:00 AM EDTHalozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthHalozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- BNK Invest · Oct 27, 10:57 AM EDTNoteworthy ETF Outflows: DFAS, SWKS, HALO, AITLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Dimensional US Small Cap ETF (Symbol: DFAS) where we have detected an approximate $308.0 million dollar outflow — that's a 2.0% decrease week over
- Zacks · Oct 26, 10:41 AM EDTTNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataTango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
- Zacks · Oct 26, 10:25 AM EDTIncyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyINCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
- Zacks · Oct 26, 10:17 AM EDTRDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
- Zacks · Oct 23, 11:08 AM EDTMRNA Tanks as Positive Phase III Cancer Therapy Data Fails to ImpressModerna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.
- Zacks · Oct 23, 8:25 AM EDTIncyte Gears Up to Report Q3 Earnings: Will Results Disappoint?INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.
- Zacks · Oct 22, 5:31 AM EDTThe Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and TeradyneCHRD, HALO, SEZL, SNDK and TER boast strong margins and growth prospects, with earnings catalysts ahead as October 2026 results roll in.
- Zacks · Oct 21, 2:00 PM EDT5 Strong Buy Growth Stocks With High Margins to Grab Before EarningsFive Strong Buy stocks stand out ahead of earnings, combining high operating margins, revenue growth and exposure to AI, healthcare, energy and digital payments.
- Zacks · Oct 21, 10:19 AM EDTELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 OutlookElevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
- Zacks · Oct 20, 8:40 AM EDTAre Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
- Zacks · Oct 19, 8:00 AM EDTThe Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme TherapeuticsRoss Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics earn top Zacks rankings, backed by growth drivers ranging from streaming ads to drug demand.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Halozyme Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.